A Research Study of the Reduction of the Effects of Cortisol in Psychotic Depression
Scientific literature suggests that high levels of cortisol have the potential to cause the psychotic symptoms associated with psychotic depression. Because mifepristone blocks the effects of cortisol, we are studying it as a potential treatment for psychotic depression. The phase 3 RECors trial is to study the efficacy and safety of mifepristone vs placebo in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features.
Enrollment at sites across the United States is currently open to qualifying patients. To learn more about the RECors Trial, including objectives, enrollment criteria, eligibility, and site locations, visit RECorsTrial.com or ClinicalTrials.gov.